

Patents and Innovations

HIGHLIGHTS

■ Life Sciences-Minded Strategic Patent Counseling

Wilson Sonsini's patents and innovations attorneys are experts in global patent portfolio development and management for a variety of life sciences clients, including start-up and established biotechnology corporations, multinational pharmaceutical corporations, and premier research universities.

■ At the Cutting-Edge of Life Sciences and Technology Innovation

Wilson Sonsini's patents and innovations professionals are responsible for developing the IP portfolios covering such inventions as CRISPR gene-editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. Our attorneys work with innovators engaged in highly technical fields, including diagnostics, genomics, bioinformatics, artificial intelligence, and materials.

■ One of the Largest Life Sciences-Focused Patent Practices in the World

Most of Wilson Sonsini's 180-plus patent attorneys, patent agents, and IP professionals possess Ph.D.s or other advanced degrees in biology, chemistry, biomedical sciences, or engineering.

■ Substantial USPTO Experience

Over 170 of Wilson Sonsini's attorneys and agents have been admitted to practice before the USPTO. Our team includes several former USPTO executives, including a former Administrative Patent Judge, a former Deputy Administrator in the Office of Policy and External Affairs, a former Deputy Commissioner for Patent Operations, and a former Deputy Commissioner for Patent Administration.

OVERVIEW

Life Sciences-Minded and Strategic Patent Counseling Expertise

Wilson Sonsini's patents and innovations practice helps clients leverage their intellectual property, defend against claims of others, and establish a competitive position for the future in fields such as therapeutics, biologics, personalized medicine, research tools, and clean technologies. Our team helps growing companies achieve important milestones by securing, developing, and protecting their most vital IP assets, while also advising established companies responsible for advancing groundbreaking discoveries. We identify the areas in which IP protection is most critical to achieving the company's business objectives, determine the most effective methods of protection, and identify strategies to avoid issues with third-party patents.


The members of Wilson Sonsini's patents and innovations team are experts in all facets of IP counseling, including the following:

- Patent portfolio management
- Preparation and prosecution of U.S. and foreign patent applications
- Interference and reexamination proceedings
- Non-infringement and validity opinions
- Freedom-to-operate and due diligence analyses
- Licensing and regulatory submissions

- Litigation enforcement and defense, including USPTO trial proceedings
- IP due diligence for initial public offerings, PIPE transactions, asset purchase agreements, and venture financings
- FDA-related submissions and strategies such as citizen petitions and Paragraph IV certification

Key Facts About Our Practice

Wilson Sonsini's patents and innovations team is comprised of more than 180 experienced patent attorneys, patent agents, and IP professionals. In 2025, the firm had more than 770 U.S. and 2,400 foreign patents issued on behalf of clients.



At the Cutting-Edge of Life Sciences and Technology Innovation

Wilson Sonsini has an impressive track record of IP value creation, as members of our practice are responsible for the development of the IP portfolios covering such inventions as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. Our patents and innovations attorneys serve clients in the following fields:

- Agricultural biotechnology
- Adoptive cell therapy
- Animal health
- Antibody therapeutics
- Biochemistry
- Bioinformatics software
- Biomedical sciences
- Biotechnology
- Catalysis and oil processing
- CAR-T cell therapies
- CRISPR gene editing
- Cell therapy
- Chemical engineering
- Digital health
- Diagnostics
- Genetic engineering
- Gene therapy
- Genetics
- Genome editing
- Genomics
- Immuno-oncology
- Medical devices
- Molecular biology, RNA-based medicines
- Nanotechnology
- Organic and medicinal chemistry
- Personalized medicine
- Peptides
- Pharmaceuticals
- Proteomics
- Solid state and inorganic chemistry
- Stem cell biology
- Small molecule therapeutics
- Synthetic biology
- Tissue engineering
- Virology

One of the Largest Life Sciences-Focused Patent Practices in the World

Wilson Sonsini's patents and innovations team—which is highly integrated with the firm's corporate, litigation, and transactional practices—is comprised of more than 180 experienced patent attorneys, patent agents, and IP professionals, most of whom possess Ph.D. or other advanced degrees in such areas as biology, chemistry, immunology, biomedical sciences, engineering, or other scientific fields.

Substantial USPTO Experience

Over 170 of Wilson Sonsini's attorneys and agents have been admitted to practice before the U.S. Patent and Trademark Office. In fact, our team includes several former USPTO executives, including a former Administrative Patent Judge, a former Deputy Administrator in the Office of Policy and External Affairs, a former Deputy Commissioner for Patent Operations, and a former Deputy Commissioner for Patent Administration.

TECHNICAL WRITING AND IPO DOCUMENTATION

Wilson Sonsini offers a suite of services for life sciences clients navigating the complexities of initial public offerings (IPOs). Leveraging the scientific expertise of the firm's Patents and Innovations and Corporate practices, our team provides specialized business and technical writing services, including drafting the business section of the registration statement, preparing investor presentations, and handling other technical writing needed during the IPO process.

Uniquely, our life sciences-focused patent team consists of more than 180 legal professionals with Ph.D.s and other advanced degrees in biology, chemistry, biomedical sciences, or engineering. Our technical writing expertise encompasses biopharmaceuticals, small molecule therapeutics, research tools, medical devices, genomics, bioinformatics, artificial intelligence, and materials. Because our professionals are credentialed scientists who are intimately familiar with the science at the core of the client's business, as scientific writers, they are well positioned to draft a Form S-1 or Form F-1 business section that meets the SEC's exacting standards for registration statements, dovetails with the client's patent strategy, and tells a compelling and exciting story about the client's technology, business, and value proposition to educate potential investors.

The firm has a 60-plus-year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini's strategic advice to establish and realize their companies' business objectives. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients. This breadth of experience informs our IPO-related scientific writing and allows us to produce optimal capitalization results for our clients.

Wilson Sonsini's IPO scientific writers are professionals in global patent portfolio development and management. They include former senior technology licensing executives at top-tier research universities and former in-house legal counsel for major life sciences companies.

The unparalleled combination of our scientific backgrounds and industry experience enables us to accelerate and streamline the IPO process by producing a business description in advance of an IPO organizational meeting, thereby allowing management to maintain its focus on operating the business.